Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success

You may also be interested in...



As Takeda Integrates Its Nycomed Acquisition, Europe Bears Brunt Of Job Cuts

Takeda is to close two R&D facilities in Germany and to cut commercial activities in the U.S., as it looks for cost savings from the 2011 acquisition of Nycomed.

PharmAsia News Favorite Stories From 2011

If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.

AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City

AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City

Related Content

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel